US 12,461,098 B2
Biomarkers for multiple sclerosis
Brian William Della Valle, Copenhagen (DK); Casper Hempel, Dyssegård (DK); and Marie Agnete Larsen, Hinnerup (DK)
Assigned to GLX Analytix ApS, Copenhagen (DK)
Filed by GLX Analytix ApS, Copenhagen (DK)
Filed on Apr. 23, 2024, as Appl. No. 18/643,880.
Application 18/643,880 is a continuation of application No. 16/772,034, granted, now 11,994,519, previously published as PCT/EP2018/084825, filed on Dec. 13, 2018.
Claims priority of application No. 17207028 (EP), filed on Dec. 13, 2017.
Prior Publication US 2024/0345081 A1, Oct. 17, 2024
Int. Cl. B01L 3/00 (2006.01); B01D 15/08 (2006.01); B01F 33/302 (2022.01); B01F 33/3033 (2022.01); B01L 7/00 (2006.01); B01L 9/00 (2006.01); B65G 47/80 (2006.01); B82Y 20/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01); C08L 5/08 (2006.01); C12M 1/34 (2006.01); C12M 3/06 (2006.01); C12N 1/14 (2006.01); C12N 1/20 (2006.01); C12Q 1/02 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6844 (2018.01); C12Q 1/6848 (2018.01); C12Q 1/686 (2018.01); G01N 15/10 (2024.01); G01N 15/14 (2024.01); G01N 15/1433 (2024.01); G01N 21/29 (2006.01); G01N 21/65 (2006.01); G01N 30/02 (2006.01); G01N 30/72 (2006.01); G01N 33/543 (2006.01); G01N 33/557 (2006.01); G01N 33/564 (2006.01); G01N 33/574 (2006.01); G01N 33/58 (2006.01)
CPC G01N 33/564 (2013.01) [C08L 5/08 (2013.01); G01N 2400/40 (2013.01); G01N 2800/285 (2013.01)] 39 Claims
OG exemplary drawing
 
1. A method for monitoring disease risk, progression, or regression of multiple sclerosis (MS) in a subject, the method comprising:
detecting levels of at least two biomarkers in a first biological sample from a subject, wherein the subject is considered as having multiple sclerosis or at risk of developing multiple sclerosis, wherein the at least two biomarkers are glycocalyx (GLX)-related molecules, wherein detecting the levels of at least two biomarkers that are GLX-related in the first biological sample from the subject comprises detecting using at least one technique selected from the group consisting of: binding agents, immunoassays, antibody recognition, multiplexing, dot blotting, beads, microspheres, single-molecule array technology, mass spectrometry, HPLC, Raman spectroscopy, NIR spectroscopy, and NMR spectroscopy;
comparing the levels of the at least two biomarkers in the first biological sample to at least one reference level for the at least two biomarkers, wherein the at least one reference level for the at least two biomarkers was determined using a statistical analysis of levels of the at least two biomarkers detected in at least one second biological sample, wherein the statistical analysis comprises at least one multivariate statistical test; and
determining that the subject has a risk, a progression, or a regression of MS based at least in part on a result of the comparing of the levels of the at least two biomarkers in the first biological sample to the at least one reference level.